Streetbeat News

PYPD

PolyPid Ltd.

https://www.polypid.com

Industry

Biotechnology

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Open

3.56

Mkt cap

24M

Volume

3K

High

3.62

P/E Ratio

-0.50

52-wk high

9.20

Low

3.55

Div yield

N/A

52-wk low

2.95

PolyPid Ltd. held its Q3 2024 earnings call, discussing financial results and company updates. Key participants included the CEO, COO, and CFO, with analysts from JMP and Craig-Hallum attending.

Portfolio Pulse from

November 13, 2024 | 7:15 pm

PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company, will participate in the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, in New York. This event could provide the company with opportunities to engage with investors and potentially impact its stock price.

Portfolio Pulse from

November 07, 2024 | 12:15 pm

PolyPid published a full dataset from its first Phase 3 study of D-PLEX100 in the International Journal of Surgery. The SHIELD I study, one of the largest in over a decade for SSI prevention in colorectal resection, showed potential benefits for high-risk patients. The ongoing SHIELD II study focuses on large surgical incisions, with results expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:08 am

HC Wainwright & Co. has reiterated its Buy rating on PolyPid (NASDAQ:PYPD) and maintained a price target of $14, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:47 am

PolyPid Ltd. has completed patient enrollment for an interim analysis in its SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections. The analysis could lead to early trial conclusion, continuation, or futility. Successful results may unlock additional funding.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 11:06 am

PolyPid has filed with the SEC for the resale of up to 3.9 million ordinary shares by selling shareholders. This move could impact the stock's supply and demand dynamics.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 8:04 pm

HC Wainwright & Co. has reiterated its Buy rating on PolyPid (NASDAQ:PYPD) and maintained a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 10:50 am

PolyPid (NASDAQ:PYPD) reported a Q2 2024 GAAP EPS of $(1.25), missing the analyst consensus estimate of $(1.18) by 5.93%.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 11:02 am

PolyPid secures up to $14M in a private placement, extending its cash runway to Q2 2025. The funding supports the ongoing SHIELD II Phase 3 trial of D-PLEX100, with top-line results expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 7:06 am

Bank of Marin Bancorp (NASDAQ:BMRC) shares fell sharply after reporting worse-than-expected quarterly earnings. Other notable stock movements include 2U, Inc. (NASDAQ:TWOU) climbing 128% and Cognition Therapeutics, Inc. (NASDAQ:CGTX) falling 34%.

Portfolio Pulse from Avi Kapoor

July 29, 2024 | 5:19 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.